SC 13G 1 dsc13g.htm SCHEDULE 13G Schedule 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

 

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.         )*

 

 

 

ACCENTIA BIOPHARMACEUTICALS, INC.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

 

00430L10

                                (CUSIP Number)                                

 

December 31, 2005

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨ Rule 13d-1(b)

 

¨ Rule 13d-1(c)

 

x Rule 13d-1(d)

 

*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP Number 00430L10

Page 2 of 4

 

  1.  

Name of Reporting Person

S.S. or I.R.S. Identification No. of Reporting Person

 

            Pharmaceutical Product Development, Inc.

    
  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ¨

(b)  ¨

    
  3.  

SEC Use Only

 

    
  4.  

Citizenship or Place of Organization

 

            North Carolina

    

Number of

Shares

Beneficially

Owned By

Each

Reporting

Person

With:

  

  5.    Sole Voting Power

 

                4,270,323

  6.    Shared Voting Power

 

                0

  7.    Sole Dispositive Power

 

                4,270,323

  8.    Shared Dispositive Power

 

                0

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

            4,270,323

    
10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

    
11.  

Percent of Class Represented by Amount in Row (9)

 

            14.7%

    
12.  

Type of Reporting Person (See Instructions)

 

            CO

    

 

 

CUSIP Number 00430L10

Page 3 of 4

 

Item 1

  

(a).

    Name of Issuer          
         Accentia BioPharmaceuticals, Inc. (the “Issuer”)          

Item 1

  

(b).

    Address of the Issuer’s Principal Executive Office          
        

324 South Hyde Park Ave., Suite 350

Tampa, Florida 33606

          

Item 2

  

(a).

    Name of Person Filing          
         The shares identified in this report are owned directly by PPD International Holdings, Inc., a wholly-owned subsidiary of PPD Development, LP. PPD Development, LP is 99.9% owned by PPD Holdings, LLC and 0.1% owned by PPD GP, LLC. Both PPD Holdings, LLC and PPD GP, LLC are wholly-owned subsidiaries of Applied Bioscience International LLC, which is a wholly-owned subsidiary of Pharmaceutical Product Development, Inc. (“PPD”), the Reporting Person.          

Item 2

  

(b).

    Address of the Filing Person’s Principal Business Office:          
        

The address of the principal business office of PPD is:

 

3151 South 17th Street

Wilmington, North Carolina 28412

          

Item 2

  

(c).

    Place of Organization          
         North Carolina          

Item 2

  

(d).

    Title of Class of Securities          
         Common Stock          

Item 2

  

(e).

    Cusip Number          
         00430L10          

Item 3.

   Filing Pursuant to Rules 13d-1(b) or 13d-2(b)     
    Not Applicable     

CUSIP Number 00430L10

Page 4 of 4

 

Item 4.

    Ownership          
     (a)    Amount Beneficially Owned: See Row (9) on Page 2.          
     (b)    Percent of Class: See Row (11) on Page 2.          
     (c)    Sole Power vs. Shared Power to Vote and Dispose of Shares: See Rows (5)-(8) on Page 2.          

Item 5.

    Ownership of Five Percent or Less of a Class     
     Not Applicable     

Item 6.

    Ownership of More than Five Percent on Behalf of Another Person          
     Not Applicable          

Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     Not Applicable

Item 8.

    Identification and Classification of Members of the Group          
     Not Applicable          

Item 9.

    Notice of Dissolution of Group          
     Not Applicable          

Item 10.

    Certification          
     After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.          

 

Dated: February 7, 2006

 

Pharmaceutical Product Development, Inc.
By:  

/s/ B. Judd Hartman

Name:   B. Judd Hartman
Title:   General Counsel